
501 - 1000 employees
Founded 2014
🏥 Healthcare
💼 Consulting
🏭 Manufacturing
💰 $350M Post-IPO Equity - Autolus on 2024-02
Healthcare • Consulting • Manufacturing
Autolus Therapeutics is a clinical-stage biotechnology company developing next-generation autologous CAR T cell therapies for cancer and autoimmune diseases. The company applies advanced cell programming, proprietary viral vectors, and semi-automated T cell manufacturing to engineer precision CAR T products, and is advancing a pipeline that includes programs for hematological malignancies, solid tumors, and autoimmune indications. Autolus emphasizes integrated development and commercialization efforts, clinical trials, and publication of its research.
Selected: 🆕 Date Added.
🔥 5 hours ago
Regulatory affairs director guiding FDA-compliant promotion, medical communications, and global labelling for Autolus cancer and autoimmune therapies. Leading cross-functional strategies, reviews, submissions, and governance.
🏖️ New Jersey – Remote
💰 $350M Post-IPO Equity - Autolus on 2024-02
⏰ Full Time
🔴 Lead
🚔 Compliance
👻 Ghost score 10%
🕒 September 4
Medical Science Liaison advancing Autolus’ CAR-T therapies for cancer and autoimmune diseases. Engaging healthcare stakeholders and supporting evidence generation, clinical trials, and patient access.
🏄 California, Colorado, +2 more states – Remote
💰 $350M Post-IPO Equity - Autolus on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
✨ Medical Science Liaison
👻 Ghost score 10%
🕒 August 5
Corporate Paralegal supporting SEC filings, state registrations, and corporate governance. Providing legal support for Autolus, a biopharmaceutical company developing programmed T-cell therapies for cancer and autoimmune disease.
🌪️ Oklahoma, Maryland, +3 more states – Remote
💰 $350M Post-IPO Equity - Autolus on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
💼 Paralegal
👻 Ghost score 17%
🕒 July 31
MSL engaging with external stakeholders in oncology to inform practice, improve patient access, and support clinical trials. Collaborating with field colleagues to leverage medical intelligence.
🍂 Massachusetts – Remote
💰 $350M Post-IPO Equity - Autolus on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
✨ Medical Science Liaison
👻 Ghost score 18%